Graham P Pawelec

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4119402/publications.pdf

Version: 2024-02-01

482 papers

28,573 citations

90 h-index 150 g-index

603 all docs

603 docs citations

603 times ranked

29371 citing authors

#	Article	IF	Citations
1	Myeloid-Derived Suppressive Cells in Ageing and Age-Related Diseases. Healthy Ageing and Longevity, 2022, , 53-64.	0.2	O
2	Muscle Mass and Inflammation in Older Adults: Impact of the Metabolic Syndrome. Gerontology, 2022, 68, 989-998.	2.8	14
3	Integrin activation enables rapid detection of functional \hat{VI} 1+ and \hat{VI} 2+ $\hat{I}^3\hat{I}$ 7 cells. European Journal of Immunology, 2022, , .	2.9	0
4	Latent CMV makes older adults less na \tilde{A} -ve. EBioMedicine, 2022, 77, 103887.	6.1	0
5	Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change. Vaccines, 2022, 10, 607.	4.4	23
6	Single-cell immune atlas for human aging and frailty., 2022, 1, 67-70.		15
7	Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Research Reviews, 2021, 65, 101205.	10.9	601
8	Associations of Cytomegalovirus Infection With All-Cause and Cardiovascular Mortality in Multiple Observational Cohort Studies of Older Adults. Journal of Infectious Diseases, 2021, 223, 238-246.	4.0	30
9	Vaccination in old age: Challenges and promises. , 2021, , 129-153.		1
10	The aging immune system: Dysregulation, compensatory mechanisms, and prospects for intervention., $2021, 345-366$.		1
11	Genetic Influence on the Peripheral Differentiation Signature of Vδ2+ γδ and CD4+ αβ T Cells in Adults. Cells, 2021, 10, 373.	4.1	2
12	Unanticipated efficacy of SARS-CoV-2 vaccination in older adults. Immunity and Ageing, 2021, 18, 7.	4.2	20
13	Human endogenous retroviruses and ageing. Immunity and Ageing, 2021, 18, 14.	4.2	3
14	Improving seasonal influenza vaccination for older adults. Immunity and Ageing, 2021, 18, 13.	4.2	0
15	Cellular Immune Phenotypes and Worsening Scores of Frailty-Associated Parameters Over an 18-Month Period in the Very Old. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1356-1361.	3.6	3
16	MDSCs, ageing and inflammageing. Cellular Immunology, 2021, 362, 104297.	3.0	30
17	Key Determinants of Cell-Mediated Immune Responses: A Randomized Trial of High Dose Vs. Standard Dose Split-Virus Influenza Vaccine in Older Adults. Frontiers in Aging, 2021, 2, .	2.6	3
18	The Journal of Ageing and Longevity: Taking a Holistic View of the Human Healthspan. Journal of Ageing and Longevity, $2021, 1, 1-2$.	0.6	0

#	Article	IF	Citations
19	Is mechanical loading essential for exercise to preserve the aging immune system?. Immunity and Ageing, 2021, 18, 26.	4.2	3
20	Does immunosenescence drive organismal ageing via inflammageing?. Immunity and Ageing, 2021, 18, 31.	4.2	3
21	Impact of Cytomegalovirus Infection and Genetic Background on the Frequencies of Peripheral Blood Suppressor Cells in Human Twins. Pathogens, 2021, 10, 963.	2.8	1
22	Catch-as-catch-can: mRNA vaccination boosts immune responses to SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2021, 6, 259.	17.1	1
23	Human CD4+ T-Cell Clone Expansion Leads to the Expression of the Cysteine Peptidase Inhibitor Cystatin F. International Journal of Molecular Sciences, 2021, 22, 8408.	4.1	3
24	Immunomonitoring of Human Breast Milk Cells During HCMV-Reactivation. Frontiers in Immunology, 2021, 12, 723010.	4.8	7
25	Functional Changes of T-Cell Subsets with Age and CMV Infection. International Journal of Molecular Sciences, 2021, 22, 9973.	4.1	20
26	Novel immunomodulatory properties of low dose cytarabine entrapped in a mannosylated cationic liposome. International Journal of Pharmaceutics, 2021, 606, 120849.	5.2	8
27	Validation of the effectiveness of SARS-CoV-2 vaccines in older adults in "real-world―settings. Immunity and Ageing, 2021, 18, 36.	4.2	6
28	Antibody and Cell-Mediated Immune Responses Are Correlates of Protection against Influenza Infection in Vaccinated Older Adults. Vaccines, 2021, 9, 25.	4.4	8
29	Editorial: Frontiers' Research Topic "Cancer Vaccines: Time to Think Differently!― Frontiers in Immunology, 2021, 12, 771319.	4.8	0
30	Multiple thymi and no thymic involution in naked mole rats?. Immunity and Ageing, 2021, 18, 41.	4.2	0
31	Granzyme B: A Double-Edged Sword in the Response to Influenza Infection in Vaccinated Older Adults. Frontiers in Aging, 2021, 2, .	2.6	3
32	Berlin Aging Study II (BASE-II)., 2021,, 649-656.		0
33	Human Immune System in Aging. , 2021, , 2484-2495.		0
34	Immunological Theory of Aging. , 2021, , 2556-2566.		0
35	4th Summer School in Immuno-Oncology, July 1st–3rd, 2021, Athens, Greece. Frontiers in Bioscience, 2021, 26, 1373.	2.1	0
36	Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. , 2021, 9, e003439.		10

#	Article	IF	CITATIONS
37	The conundrum of human immune system "senescence― Mechanisms of Ageing and Development, 2020, 192, 111357.	4.6	64
38	Lack of consensus on an aging biology paradigm? A global survey reveals an agreement to disagree, and the need for an interdisciplinary framework. Mechanisms of Ageing and Development, 2020, 191, 111316.	4.6	67
39	The human immunosenescence phenotype: does it exist?. Seminars in Immunopathology, 2020, 42, 537-544.	6.1	22
40	Invited Editorial: Despite COVID-19, Influenza Must Not Be Relegated to "Only the Sniffles― Vaccines, 2020, 8, 445.	4.4	0
41	Identification of Tumor Antigen-Specific T Cells in the Peripheral Blood of Colorectal Cancer Patients. Journal of the American College of Surgeons, 2020, 231, S57.	0.5	0
42	T cell phenotypes associated with insulin resistance: results from the Berlin Aging Study II. Immunity and Ageing, 2020, 17, 40.	4.2	11
43	The inherent challenges of classifying senescence—Response. Science, 2020, 368, 595-596.	12.6	5
44	The immune response to influenza in older humans: beyond immune senescence. Immunity and Ageing, 2020, 17, 10.	4.2	97
45	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research, 2020, 26, 5232-5245.	7.0	52
46	Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer. Frontiers in Immunology, 2020, 11, 1152.	4.8	6
47	Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Frontiers in Immunology, 2020, 11, 369.	4.8	291
48	Aging as an inflammatory disease and possible reversal strategies. Journal of Allergy and Clinical Immunology, 2020, 145, 1355-1356.	2.9	11
49	Immune compromise in the elderly. , 2020, , 1001-1006.		0
50	Intake of dietary advanced glycation end products influences inflammatory markers, immune phenotypes, and antiradical capacity of healthy elderly in a littleâ€studied population. Food Science and Nutrition, 2020, 8, 1046-1057.	3.4	20
51	Pitfalls in the characterization of circulating and tissue-resident human $\hat{I}^3\hat{I}$ T cells. Journal of Leukocyte Biology, 2020, 107, 1097-1105.	3.3	12
52	Influenza Vaccination: Accelerating the Process for New Vaccine Development in Older Adults. Interdisciplinary Topics in Gerontology and Geriatrics, 2020, 43, 98-112.	2.6	6
53	Can an effective SARS-CoV-2 vaccine be developed for the older population?. Immunity and Ageing, 2020, 17, 8.	4.2	43
54	758â€Identification of tumor antigen-specific T cells in the peripheral blood of colorectal cancer patients. , 2020, 8, A806-A806.		1

#	Article	IF	CITATIONS
55	Recent advances in influenza vaccines. F1000Research, 2020, 9, 305.	1.6	13
56	Immunosenescence, Oxidative Stress, and Cancers. , 2020, , 513-531.		0
57	Possible causes of disparities in the risk and outcomes of COVID-19: Cytomegalovirus and aged immune phenotype. Journal of Clinical and Translational Research, 2020, 6, 92-93.	0.3	2
58	838â€Phenotypic and functional signatures of peripheral and tumor-resident γδT cells are informative for outcome of checkpoint blockade in melanoma. , 2020, , .		0
59	Does patient age influence anti-cancer immunity?. Seminars in Immunopathology, 2019, 41, 125-131.	6.1	60
60	Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PLoS ONE, 2019, 14, e0221301.	2.5	16
61	Editorial: Immunology of Aging. Frontiers in Immunology, 2019, 10, 1614.	4.8	9
62	To help aging populations, classify organismal senescence. Science, 2019, 366, 576-578.	12.6	42
63	Is There a Positive Side to T Cell Exhaustion?. Frontiers in Immunology, 2019, 10, 111.	4.8	32
64	Expansion and Determination of Antigen-Reactive T Cells by Flow Cytometry. Methods in Molecular Biology, 2019, 1913, 141-151.	0.9	2
65	Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy. Clinical Breast Cancer, 2019, 19, 433-442.	2.4	5
66	Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity. Frontiers in Immunology, 2019, 10, 1099.	4.8	96
67	The immune-nutrition interplay in aging – facts and controversies. Nutrition and Healthy Aging, 2019, 5, 73-95.	1.1	11
68	Research on immunity and ageing comes of age. Immunity and Ageing, 2019, 16, 8.	4.2	2
69	Are skin senescence and immunosenescence linked within individuals?. Aging Cell, 2019, 18, e12956.	6.7	22
70	The Immune System and Its Dysregulation with Aging. Sub-Cellular Biochemistry, 2019, 91, 21-43.	2.4	155
71	Zoster Vaccination in Older Adults: Efficacy and Public Health Implications. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1239-1243.	3.6	10
72	Network topology dynamics of circulating biomarkers and cognitive performance in older Cytomegalovirus-seropositive or -seronegative men and women. Immunity and Ageing, 2019, 16, 31.	4.2	6

#	Article	IF	CITATIONS
73	Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications. Drugs and Aging, 2019, 36, 29-37.	2.7	60
74	Immune signatures associated with mortality differ in elderly populations from different birth cohorts and countries even within northern Europe. Mechanisms of Ageing and Development, 2019, 177, 182-185.	4.6	16
75	Berlin Aging Study II (BASE-II)., 2019, , 1-8.		3
76	Immunological Theory of Aging. , 2019, , 1-10.		1
77	Immune Parameters Associated with Mortality in Longitudinal Studies of Very Old People Can Be Markedly Dissimilar Even in Apparently Similar Populations. Healthy Ageing and Longevity, 2019, , 253-262.	0.2	0
78	Effect of Intrinsic and Extrinsic Lipids on T Cell Signaling. , 2019, , 2661-2677.		0
79	Human Immune System in Aging. , 2019, , 1-12.		0
80	Clonal Culture Models of T Cell Senescence. , 2019, , 193-207.		0
81	Role of Immunosenescence in Infections and Sepsis in the Elderly. , 2019, , 1883-1896.		0
82	Abstract A135: Combining low-dose chemotherapy with an NK cell-based immunotherapy as a treatment for triple-negative breast cancer. , 2019, , .		1
83	Inhibiting HSP90 prevents the induction of myeloid-derived suppressor cells by melanoma cells. Cellular Immunology, 2018, 327, 68-76.	3.0	10
84	Role of the peripheral innate immune system in the development of Alzheimer's disease. Experimental Gerontology, 2018, 107, 59-66.	2.8	114
85	Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival. Journal of Geriatric Oncology, 2018, 9, 606-612.	1.0	5
86	Immune signatures predicting responses to immunomodulatory antibody therapy. Current Opinion in Immunology, 2018, 51, 91-96.	5.5	7
87	Vaccines for Improved Cellular Immunity to Influenza. EBioMedicine, 2018, 30, 12-13.	6.1	5
88	Age and immunity: What is "immunosenescence�. Experimental Gerontology, 2018, 105, 4-9.	2.8	337
89	Immune correlates of clinical outcome in melanoma. Immunology, 2018, 153, 415-422.	4.4	9
90	CD14+ÂHLA-DRâ^'/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation. Breast Cancer Research and Treatment, 2018, 168, 401-411.	2.5	22

#	Article	IF	Citations
91	Immune parameters associated with mortality in the elderly are context-dependent: lessons from Sweden, Holland and Belgium. Biogerontology, 2018, 19, 537-545.	3.9	22
92	2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15–17, 2016, Athens, Greece. Cancer Immunology, Immunotherapy, 2018, 67, 153-159.	4.2	0
93	Effect of Intrinsic and Extrinsic Lipids on T-Cell Signaling. , 2018, , 1-18.		0
94	CASIN the joint: immune aging at the stem cell level. Blood, 2018, 132, 553-554.	1.4	7
95	Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 1845-1851.	4.2	28
96	Relationships between the inflammatory potential of the diet, aging and anthropometric measurements inÂaÂcross-sectional study in Pakistan. Nutrition and Healthy Aging, 2018, 4, 335-343.	1.1	24
97	Involvement of MicroRNAs in the Aging-Related Decline of CD28 Expression by Human T Cells. Frontiers in Immunology, 2018, 9, 1400.	4.8	13
98	Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer's Disease?. Frontiers in Aging Neuroscience, 2018, 10, 224.	3.4	155
99	Immunological Methods and the Concept of Inflammaging in the Study of Human Aging., 2018,, 45-58.		0
100	Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma?. Clinical Cancer Research, 2018, 24, 5193-5194.	7.0	5
101	Clonal Culture Models of T Cell Senescence. , 2018, , 1-15.		0
102	Role of Immunosenescence in Infections and Sepsis in the Elderly. , 2018, , 1-15.		0
103	CD4:8 Ratio Above 5 Is Associated With All-Cause Mortality in CMV-Seronegative Very Old Women: Results From the BELFRAIL Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw215.	3.6	17
104	Assessment of health status by molecular measures in adults ranging from middle-aged to old: Ready for clinical use?. Experimental Gerontology, 2017, 87, 175-181.	2.8	9
105	Immunosenescence and cancer. Biogerontology, 2017, 18, 717-721.	3.9	120
106	Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. Breast Cancer Research, 2017, 19, 20.	5.0	32
107	Contribution of neuroinflammation and immunity to brain aging and the mitigating effects of physical and cognitive interventions. Neuroscience and Biobehavioral Reviews, 2017, 75, 114-128.	6.1	193
108	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer, 2017, 73, 61-70.	2.8	88

#	Article	IF	Citations
109	Alteration of high-density lipoprotein functionality in Alzheimer's disease patients. Canadian Journal of Physiology and Pharmacology, 2017, 95, 894-903.	1.4	14
110	Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients. Journal of Immunology, 2017, 198, 927-936.	0.8	33
111	Are lower antibody responses to influenza vaccination in cytomegalovirus-seropositive older adults the result of beta adrenergic blockade?. Brain, Behavior, and Immunity, 2017, 61, 12-13.	4.1	2
112	Polymorphonuclear Neutrophil Functions are Differentially Altered in Amnestic Mild Cognitive Impairment and Mild Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2017, 60, 23-42.	2.6	24
113	Frequencies of peripheral immune cells in older adults following seasonal influenza vaccination with an adjuvanted vaccine. Vaccine, 2017, 35, 4330-4338.	3.8	8
114	KEYNOTE-006: a success in melanoma, but a long way to go. Lancet, The, 2017, 390, 1816-1817.	13.7	1
115	Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer., 2017, 5, 39.		56
116	The Role of CMV in Immunosenescence. , 2017, , 53-68.		4
117	Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients. Breast Cancer Research and Treatment, 2017, 161, 51-62.	2.5	8
118	Prognostic impact of the putative cancer stem cell markers ABCG 2, CD 133, ALDH 1A1 and CD 44V7/8 in metastatic melanoma. British Journal of Dermatology, 2017, 177, 1447-1449.	1.5	5
119	Cellular Senescence, Immunosenescence and HIV. Interdisciplinary Topics in Gerontology and Geriatrics, 2017, 42, 28-46.	2.6	28
120	Does the human immune system ever really become "senescent�. F1000Research, 2017, 6, 1323.	1.6	42
121	Differential Phenotypes of Myeloid-Derived Suppressor and T Regulatory Cells and Cytokine Levels in Amnestic Mild Cognitive Impairment Subjects Compared to Mild Alzheimer Diseased Patients. Frontiers in Immunology, 2017, 8, 783.	4.8	54
122	Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection. Frontiers in Immunology, 2017, 8, 784.	4.8	66
123	Immunosenescence and cancer immunotherapy Journal of Clinical Oncology, 2017, 35, 42-42.	1.6	0
124	Proportions of blood-borne \hat{Vl} 1+ and \hat{Vl} 2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer, 2016, 64, 116-126.	2.8	54
125	Income and Markers of Immunological Cellular Aging. Psychosomatic Medicine, 2016, 78, 657-666.	2.0	32
126	Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4 + and CD8 + T-ce responses in older adults positively correlates with response size. Scientific Reports, 2016, 6, 19227.	اا _{3.3}	44

#	Article	IF	CITATIONS
127	The inflammatory markers CRP, IL-6, and IL-10 are associated with cognitive functionâ€"data from the Berlin Aging Study II. Neurobiology of Aging, 2016, 38, 112-117.	3.1	113
128	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 4848-4858.	7.0	146
129	Editorial. Gerontology, 2016, 62, 311-315.	2.8	98
130	Editorial. Mechanisms of Ageing and Development, 2016, 158, 1-2.	4.6	0
131	Cytomegalovirus Infection Minimally Affects the Frequencies of B-Cell Phenotypes in Peripheral Blood of Younger and Older Adults. Gerontology, 2016, 62, 323-329.	2.8	14
132	Does cytomegalovirus infection contribute to socioeconomic disparities in all-cause mortality?. Mechanisms of Ageing and Development, 2016, 158, 53-61.	4.6	23
133	Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 72, glw216.	3.6	50
134	Perspectives in immunotherapy: meeting report from the "lmmunotherapy Bridgeâ€, Napoli, December 5th 2015. , 2016, 4, .		0
135	Phenotypic characterization and prognostic impact of circulating γÎ′ and αβ <scp>T</scp> â€cells in metastatic malignant melanoma. International Journal of Cancer, 2016, 138, 698-704.	5.1	24
136	PTSD is associated with an increase in aged T cell phenotypes in adults living in Detroit. Psychoneuroendocrinology, 2016, 67, 133-141.	2.7	39
137	Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer. Journal of Translational Medicine, 2016, 14, 151.	4.4	37
138	A clinical and biological perspective of human myeloid-derived suppressor cells in cancer. Cellular and Molecular Life Sciences, 2016, 73, 4043-4061.	5.4	55
139	Ageing and Senescence in Immune Cells In Vitro and In Vivo. Healthy Ageing and Longevity, 2016, , 85-95.	0.2	0
140	No strong correlations between serum cytokine levels, CMV serostatus and hand-grip strength in older subjects in the Berlin BASE-II cohort. Biogerontology, 2016, 17, 189-198.	3.9	25
141	Genetic Influence on the Peripheral Blood CD4 ⁺ T-cell Differentiation Status in CMV Infection. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1537-1543.	3.6	14
142	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 2908-2918.	7.0	459
143	The Aging Immune System. , 2016, , 407-431.		1
144	Responses of Dendritic Cells to TLR-4 Stimulation Are Maintained in the Elderly and Resist the Effects of CMV Infection Seen in the Young. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1117-1123.	3.6	21

#	Article	IF	Citations
145	Altered dendritic cell subset distribution in patients with Parkinson's disease: Impact of CMV serostatus. Journal of Neuroimmunology, 2016, 290, 60-65.	2.3	15
146	Natural killer cells, ageing and cancer. Cancer Immunology, Immunotherapy, 2016, 65, 367-370.	4.2	14
147	From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation. Biogerontology, 2016, 17, 147-157.	3.9	128
148	\hat{V} 2+ and \hat{I} ± \hat{I} 2 T cells show divergent trajectories during human aging. Oncotarget, 2016, 7, 44906-44918.	1.8	17
149	The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget, 2016, 7, 29977-29988.	1.8	39
150	Peripheral Immune Signatures in Alzheimer Disease. Current Alzheimer Research, 2016, 13, 739-749.	1.4	46
151	Characterization of γδT-cells via flow cytometry. Age, 2015, 37, 123.	3.0	1
152	Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients., 2015, 3, 45.		9
153	NK Cells are Activated in Amnestic Mild Cognitive Impairment but not in Mild Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2015, 46, 93-107.	2.6	46
154	Peripheral blood T-cell signatures from high-resolution immune phenotyping of $\hat{l}^3\hat{l}$ and $\hat{l}\pm\hat{l}^2$ T-cells in younger and older subjects in the Berlin Aging Study II. Immunity and Ageing, 2015, 12, 25.	4.2	34
155	Higher Lipoprotein (a) Levels Are Associated with Better Pulmonary Function in Community-Dwelling Older People – Data from the Berlin Aging Study II. PLoS ONE, 2015, 10, e0139040.	2.5	7
156	CCR4 ⁺ Regulatory T Cells Accumulate in the Very Elderly and Correlate With Superior 8-Year Survival. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 917-923.	3.6	22
157	IL7R gene expression network associates with human healthy ageing. Immunity and Ageing, 2015, 12, 21.	4.2	39
158	As we age: Does slippage of quality control in the immune system lead to collateral damage?. Ageing Research Reviews, 2015, 23, 116-123.	10.9	50
159	CD4:8 Ratio >5 Is Associated With a Dominant Naive T-Cell Phenotype and Impaired Physical Functioning in CMV-Seropositive Very Elderly People: Results From the BELFRAIL Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 143-154.	3.6	30
160	Impact of age, sex and CMV-infection on peripheral T cell phenotypes: results from the Berlin BASE-II Study. Biogerontology, 2015, 16, 631-643.	3.9	104
161	Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Research, 2015, 17, 34.	5.0	63
162	Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Seminars in Cancer Biology, 2015, 35, S185-S198.	9.6	1,122

#	Article	IF	CITATIONS
163	Predictors of the antibody response to influenza vaccination in older adults with type 2 diabetes. BMJ Open Diabetes Research and Care, 2015, 3, e000140.	2.8	59
164	Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015. Cancer Immunology, Immunotherapy, 2015, 64, 1071-1074.	4.2	6
165	Frailty, Inflammation and Immunosenescence. Interdisciplinary Topics in Gerontology and Geriatrics, 2015, 41, 26-40.	2.6	79
166	The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma. Oncolmmunology, 2015, 4, e955683.	4.6	4
167	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	9.6	220
168	Age-Associated Differences in MiRNA Signatures Are Restricted to CD45RO Negative T Cells and Are Associated with Changes in the Cellular Composition, Activation and Cellular Ageing. PLoS ONE, 2015, 10, e0137556.	2.5	23
169	Immunosenescence, Oxidative Stress, and Cancers. , 2015, , 377-393.		0
170	Abstract P4-09-01: Impact of adjuvant chemotherapy on clinical and biological ageing in older breast cancer patients. , 2015 , , .		1
171	Abstract 1311: The frequency of circulating $\hat{V}(1-p)$ positive but not $\hat{V}(2-p)$ positive $\hat{J}(1-p)$ cells correlates negatively with survival in late-stage melanoma and may be increased by ipilimumab treatment., 2015, , .		0
172	On the Immunological Theory of Aging. Interdisciplinary Topics in Gerontology, 2014, 39, 163-176.	3.6	87
173	Monocytic myeloid-derived suppressor cells in advanced melanoma patients. Oncolmmunology, 2014, 3, e27845.	4.6	17
174	Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells. Clinical Cancer Research, 2014, 20, 1601-1609.	7.0	222
175	Evidence for Less Marked Potential Signs of T-Cell Immunosenescence in Centenarian Offspring Than in the General Age-Matched Population. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 495-504.	3.6	17
176	Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses. Cancer Immunology Research, 2014, 2, 668-678.	3.4	81
177	Cohort Profile: The Berlin Aging Study II (BASE-II)â€. International Journal of Epidemiology, 2014, 43, 703-712.	1.9	213
178	SENIEUR status of the originating cell donor negates certain †anti-immunosenescence†deffects of ebselen and N-acetyl cysteine in human T cell clone cultures. Immunity and Ageing, 2014, 11, 17.	4.2	5
179	Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. Clinical Cancer Research, 2014, 20, 4390-4399.	7.0	36
180	Aging and immunity – Impact of behavioral intervention. Brain, Behavior, and Immunity, 2014, 39, 8-22.	4.1	76

#	Article	IF	CITATIONS
181	Rudimentary signs of immunosenescence in Cytomegalovirus-seropositive healthy young adults. Age, 2014, 36, 287-297.	3.0	76
182	Evaluating the physiological reserves of older patients with cancer: The value of potential biomarkers of aging? Journal of Geriatric Oncology, 2014, 5, 204-218.	1.0	74
183	Better immunity in later life: a position paper. Age, 2014, 36, 9619.	3.0	11
184	Inflammation, ageing and chronic disease. Current Opinion in Immunology, 2014, 29, 23-28.	5.5	333
185	Latent Infection with Cytomegalovirus Is Associated with Poor Memory CD4 Responses to Influenza A Core Proteins in the Elderly. Journal of Immunology, 2014, 193, 3624-3631.	0.8	103
186	Aging, Immunosenescence, and Cancer. , 2014, , 55-69.		2
187	Immunosenenescence: Role of cytomegalovirus. Experimental Gerontology, 2014, 54, 1-5.	2.8	151
188	OMIPâ€020: Phenotypic characterization of human γÎ′ T ells by multicolor flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 522-524.	1.5	25
189	T-cell immunity in the aging human. Haematologica, 2014, 99, 795-797.	3.5	47
190	Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses Journal of Clinical Oncology, 2014, 32, 9041-9041.	1.6	2
191	Immune Compromise in the Elderly. , 2014, , 811-814.		0
192	Abstract 2547: Peripheral immune signatures and survival in stage IV melanoma., 2014,,.		0
193	Age-associated alterations in $\hat{I}^3\hat{I}$ T-cells are present predominantly in individuals infected with Cytomegalovirus. Immunity and Ageing, 2013, 10, 26.	4.2	41
194	Immunosenescence in vertebrates and invertebrates. Immunity and Ageing, 2013, 10, 12.	4.2	91
195	An investigation of the effects of the antioxidants, ebselen or N-acetyl cysteine on human peripheral blood mononuclear cells and T cells. Immunity and Ageing, 2013, 10, 7.	4.2	15
196	Multiâ€parametric phosphoâ€flow cytometry: A crucial tool for T lymphocyte signaling studies. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 265-272.	1.5	8
197	Hsps are up-regulated in melanoma tissue and correlate with patient clinical parameters. Cell Stress and Chaperones, 2013, 18, 145-154.	2.9	20
198	A novel B cell population revealed by a CD38/CD24 gating strategy: CD38â^'CD24â^' B cells in centenarian offspring and elderly people. Age, 2013, 35, 2009-2024.	3.0	57

#	Article	IF	CITATIONS
199	Aging affects the proportions of T and B cells in a group of elderly men in a developing country—a pilot study from Pakistan. Age, 2013, 35, 1521-1530.	3.0	34
200	Lower proportion of $na\tilde{A}^-$ ve peripheral CD8+ T cells and an unopposed pro-inflammatory response to human Cytomegalovirus proteins in vitro are associated with longer survival in very elderly people. Age, 2013, 35, 1387-1399.	3.0	84
201	Immunology of Aging and Cancer Development. Interdisciplinary Topics in Gerontology, 2013, 38, 38-48.	3.6	26
202	Introduction to Ageing of the Adaptive Immune System. , 2013, , 17-33.		2
203	Prothymosin α and a prothymosin α-derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes. BMC Immunology, 2013, 14, 43.	2.2	22
204	Gene expression analysis of <scp>mTOR</scp> pathway: association with human longevity. Aging Cell, 2013, 12, 24-31.	6.7	104
205	Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine, 2013, 31, 685-690.	3.8	115
206	Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identifies a Link Between p14ARF and RARͲ Signaling. Molecular Cancer Research, 2013, 11, 1166-1178.	3.4	23
207	Human T Cell Aging and the Impact of Persistent Viral Infections. Frontiers in Immunology, 2013, 4, 271.	4.8	315
208	Enhanced Chemokine Receptor Expression on Leukocytes of Patients with Alzheimer's Disease. PLoS ONE, 2013, 8, e66664.	2.5	45
209	Immunosenescence and Cancer. Critical Reviews in Oncogenesis, 2013, 18, 489-513.	0.4	75
210	Abstract A61: MDSC phenotypes but not Tregs predict patient survival in unresectable stage IV melanoma independently of the type of treatment applied , 2013, , .		0
211	Elusive Alzheimer's disease: can immune signatures help our understanding of this challenging disease? Part 1: clinical and historical background. Discovery Medicine, 2013, 15, 23-32.	0.5	11
212	Elusive Alzheimer's disease: can immune signatures help our understanding of this challenging disease? Part 2: new immune paradigm. Discovery Medicine, 2013, 15, 33-42.	0.5	17
213	FLOW CYTOMETRIC LYMPHOCYTE SUBSET ANALYSIS USING MATERIAL FROM FROZEN WHOLE BLOOD. Journal of Immunoassay and Immunochemistry, 2012, 33, 128-139.	1.1	17
214	Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. Journal of Clinical Oncology, 2012, 30, 1835-1841.	1.6	112
215	The nascent field of AllergoOncology. Cancer Immunology, Immunotherapy, 2012, 61, 1355-1357.	4.2	22
216	T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. Immunity, 2012, 37, 1-2.	14.3	131

#	Article	lF	Citations
217	The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine, 2012, 30, 2060-2067.	3.8	201
218	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	4.4	676
219	Hallmarks of human "immunosenescence― adaptation or dysregulation?. Immunity and Ageing, 2012, 9, 15.	4.2	193
220	Nutritional status influences peripheral immune cell phenotypes in healthy men in rural Pakistan. Immunity and Ageing, 2012, 9, 16.	4.2	26
221	Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old. Results from the Leiden 85-plus Study. Immunity and Ageing, 2012, 9, 18.	4.2	59
222	Aging, immunosenescence and membrane rafts: the lipid connection. Longevity & Healthspan, 2012, 1, 6.	6.7	35
223	The impact of CMV infection on survival in older humans. Current Opinion in Immunology, 2012, 24, 507-511.	5.5	131
224	CMV and Immunosenescence: from basics to clinics. Immunity and Ageing, 2012, 9, 23.	4.2	158
225	Effect of Culture at Low Oxygen Tension on the Expression of Heat Shock Proteins in a Panel of Melanoma Cell Lines. PLoS ONE, 2012, 7, e37475.	2.5	9
226	Higher estimates of daily dietary net endogenous acid production (NEAP) in the elderly as compared to the young in a healthy, free-living elderly population of Pakistan. Clinical Interventions in Aging, 2012, 7, 565.	2.9	11
227	Aging, nutrition and immunity – their relationship and interaction. Nutrition and Aging (Amsterdam,) Tj ETQq1	1 8.3843	14 _g gBT /Ove
228	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine, 2012, 18, 1254-1261.	30.7	721
229	Vaccination in the elderly. Microbial Biotechnology, 2012, 5, 226-232.	4.2	42
230	Impairment of the ABCA1 and SR-BI-mediated cholesterol efflux pathways and HDL anti-inflammatory activity in Alzheimer's disease. Mechanisms of Ageing and Development, 2012, 133, 20-29.	4.6	37
231	Immune profiling of Alzheimer patients. Journal of Neuroimmunology, 2012, 242, 52-59.	2.3	126
232	Abstract 5365: Prolonged survival of patients with advanced renal cancer responding to multi-peptide vaccine IMA901 after single-dose cyclophosphamide. , 2012, , .		0
233	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
234	Impact of age on T cell signaling: A general defect or specific alterations?. Ageing Research Reviews, 2011, 10, 370-378.	10.9	99

#	Article	IF	CITATIONS
235	Role of CMV in immune senescence. Virus Research, 2011, 157, 175-179.	2.2	185
236	Seropositivity to Cytomegalovirus, Inflammation, All-Cause and Cardiovascular Disease-Related Mortality in the United States. PLoS ONE, 2011, 6, e16103.	2.5	321
237	Relationship between anthropometric variables and nutrient intake in apparently healthy male elderly individuals: A study from Pakistan. Nutrition Journal, 2011, 10, 111.	3.4	18
238	Report from the second cytomegalovirus and immunosenescence workshop. Immunity and Ageing, 2011, 8, 10.	4.2	35
239	Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. Journal of General Virology, 2011, 92, 2746-2756.	2.9	162
240	Association of IFN- \hat{I}^3 Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines. Clinical Cancer Research, 2011, 17, 2668-2678.	7.0	67
241	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical Cancer Research, 2011, 17, 3064-3076.	7.0	108
242	Aging, immunity, and cancer. Discovery Medicine, 2011, 11, 537-50.	0.5	111
243	Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. Cancer Immunology, Immunotherapy, 2010, 59, 1273-1284.	4.2	41
244	Aging, frailty and age-related diseases. Biogerontology, 2010, 11, 547-563.	3.9	489
245	Senescence of the Human Immune System. Journal of Comparative Pathology, 2010, 142, S39-S44.	0.4	153
246	Reduced oxygen tension results in reduced human T cell proliferation and increased intracellular oxidative damage and susceptibility to apoptosis upon activation. Free Radical Biology and Medicine, 2010, 48, 26-34.	2.9	27
247	High response rate after intratumoral treatment with interleukinâ€2. Cancer, 2010, 116, 4139-4146.	4.1	120
248	Immunosenescence and cancer. Critical Reviews in Oncology/Hematology, 2010, 75, 165-172.	4.4	110
249	Immunosenescence and Cytomegalovirus: where do we stand after a decade?. Immunity and Ageing, 2010, 7, 13.	4.2	69
250	Potential role of immunosenescence in cancer development. Annals of the New York Academy of Sciences, 2010, 1197, 158-165.	3.8	134
251	Hallmark Features of Immunosenescence Are Absent in Familial Longevity. Journal of Immunology, 2010, 185, 4618-4624.	0.8	147
252	Immunosenescence and cancer. Journal of Geriatric Oncology, 2010, 1, 20-26.	1.0	8

#	Article	IF	Citations
253	Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9470-9475.	7.1	452
254	Abstract 5582: NY-ESO-1-specific T-cells in melanoma patients with good clinical outcome after vaccination using mRNA as the immunogen. , $2010, \dots$		0
255	Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART-1-specific CD8+ T cells. International Immunology, 2009, 21, 53-62.	4.0	7
256	Immunosenescence and Vaccination in Nursing Home Residents. Clinical Infectious Diseases, 2009, 48, 443-448.	5.8	92
257	Pretreatment frequency of circulating ILâ€17 ⁺ CD4 ⁺ Tâ€cells, but not Tregs, correlates with clinical response to wholeâ€cell vaccination in prostate cancer patients. International Journal of Cancer, 2009, 125, 1372-1379.	5.1	108
258	From bench to bedside and back: the SENIEUR Protocol and the efficacy of influenza vaccination in the elderly. Biogerontology, 2009, 10, 83-94.	3.9	57
259	Relationships between cancer and aging: a multilevel approach. Biogerontology, 2009, 10, 323-338.	3.9	60
260	The European searchable tumour line database. Cancer Immunology, Immunotherapy, 2009, 58, 1501-1506.	4.2	16
261	Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunology, Immunotherapy, 2009, 58, 1517-1526.	4.2	111
262	Impact of aging on cancer immunity and immunotherapy. Cancer Immunology, Immunotherapy, 2009, 58, 1907-1908.	4.2	24
263	Cytomegalovirus and human immunosenescence. Reviews in Medical Virology, 2009, 19, 47-56.	8.3	297
264	Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Current Opinion in Immunology, 2009, 21, 440-445.	5.5	206
265	Dramatic Shifts in Circulating CD4 but not CD8 T Cell Subsets in Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 91-103.	2.6	173
266	Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas. Cancer Research, 2009, 69, 8412-8419.	0.9	82
267	Immune therapy for age-related diseases. Trends in Immunology, 2009, 30, 344-350.	6.8	33
268	Prothymosin \hat{l}_{\pm} immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a \hat{l}^2 -sheet conformation in a sequence-specific manner. Molecular Immunology, 2009, 46, 784-792.	2.2	34
269	Mechanisms of immunosenescence. Immunity and Ageing, 2009, 6, 10.	4.2	103
270	Immunosenescence and vaccine failure in the elderly. Aging Clinical and Experimental Research, 2009, 21, 201-209.	2.9	234

#	Article	IF	Citations
271	Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients. Journal of Immunotherapy, 2009, 32, 498-507.	2.4	301
272	NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood, 2009, 113, 358-369.	1.4	45
273	Accumulations of KIR+ T cells in the elderly. Blood, 2009, 114, 3360-3361.	1.4	1
274	Induction of HIF- $1\hat{l}_{\pm}$ and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells. Journal of Leukocyte Biology, 2009, 87, 265-273.	3.3	46
275	Role of Immunosenescence in Infections and Sepsis in the Elderly. , 2009, , 965-977.		3
276	Clonal Culture Models of T-cell Senescence. , 2009, , 107-115.		1
277	Effect of Intrinsic and Extrinsic Lipids on T-cell Signalling. , 2009, , 1437-1451.		0
278	The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunology, Immunotherapy, 2008, 57, 289-302.	4.2	138
279	Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunology, Immunotherapy, 2008, 57, 719-729.	4.2	43
280	Immunity, ageing and cancer. Immunity and Ageing, 2008, 5, 11.	4.2	131
281	Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immunity and Ageing, 2008, 5, 6.	4.2	275
282	Metallothionein Downregulation in Very Old Age: A Phenomenon Associated with Cellular Senescence?. Rejuvenation Research, 2008, 11, 455-459.	1.8	29
283	Aging of the Immune System as a Prognostic Factor for Human Longevity. Physiology, 2008, 23, 64-74.	3.1	273
284	Altered Expression of Mismatch Repair Proteins Associated with Acquisition of Microsatellite Instability in a Clonal Model of Human T Lymphocyte Aging. Rejuvenation Research, 2008, 11, 565-572.	1.8	19
285	Immune Receptor Signaling, Aging and Autoimmunity. Advances in Experimental Medicine and Biology, 2008, 640, 312-324.	1.6	51
286	Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders. Current Cancer Therapy Reviews, 2008, 4, 111-119.	0.3	1
287	Microsatellite Instability and Compromized Mismatch Repair Gene Expression During In Vitro Passaging of Monoclonal Human T Lymphocytes. Rejuvenation Research, 2007, 10, 145-156.	1.8	17
288	SELDI-TOF-MS ProteinChip array profiling of T-cell clones propagated in long-term culture identifies human profilin-1 as a potential bio-marker of immunosenescence. Proteome Science, 2007, 5, 7.	1.7	29

#	Article	IF	CITATIONS
289	Role of persistent CMV infection in configuring T cell immunity in the elderly. Immunity and Ageing, 2007, 4, 2.	4.2	86
290	Immunosenescence comes of age. EMBO Reports, 2007, 8, 220-223.	4.5	37
291	Gene expression changes in longâ€ŧerm culture of Tâ€ɛell clones: genomic effects of chronic antigenic stress in aging and immunosenescence. Aging Cell, 2007, 6, 155-163.	6.7	26
292	No Immune Risk Profile among individuals who reach 100 years of age: Findings from the Swedish NONA immune longitudinal study. Experimental Gerontology, 2007, 42, 753-761.	2.8	184
293	Oxidative stress modulation and T cell activation. Experimental Gerontology, 2007, 42, 852-858.	2.8	88
294	Impact of CMV and EBV seropositivity on CD8 T lymphocytes in an old population from West-Sicily. Experimental Gerontology, 2007, 42, 995-1002.	2.8	35
295	Immunity and ageing in man: Annual review 2006/2007. Experimental Gerontology, 2007, 43, 34-8.	2.8	81
296	Cytomegalovirus Infection. Annals of the New York Academy of Sciences, 2007, 1114, 23-35.	3.8	214
297	HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunology, Immunotherapy, 2007, 56, 1885-1895.	4.2	24
298	Immunosenescence., 2007,,.		4
299	Immune Risk Phenotypes and Associated Parameters in Very Old Humans: A Review of Findings in the Swedish NONA Immune Longitudinal Study. , 2007, , 1-14.		3
300	Immunosupportive therapies in aging. Clinical Interventions in Aging, 2007, 2, 33-54.	2.9	49
301	SELDI Proteomics Approach to Identify Proteins Associated with T-Cell Clone Senescence. , 2007, , 174-190.		0
302	T-Cell Signalling, a Complex Process for T-Cell Activation Compromised with Aging: When Membrane Rafts Can Simplify Everything., 2007,, 57-67.		0
303	T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenescence?. Aging Clinical and Experimental Research, 2006, 18, 171-173.	2.9	36
304	Current Strategies for the Identification of Immunogenic Epitopes of Tumor Antigens., 2006,, 21-44.		2
305	Immunorejuvenation in the Elderly. Rejuvenation Research, 2006, 9, 111-116.	1.8	30
306	Aging and Innate Immunity. Immunity, 2006, 24, 491-494.	14.3	281

#	Article	IF	CITATIONS
307	Age and immunity. Immunity and Ageing, 2006, 3, 2.	4.2	40
308	Zinc, oxidative stress, genetic background and immunosenescence: implications for healthy ageing. Immunity and Ageing, 2006, 3, 6.	4.2	23
309	Human Immunosenescence: Does It Have an Infectious Component?. Annals of the New York Academy of Sciences, 2006, 1067, 56-65.	3.8	79
310	The Genetics of Human Longevity. Annals of the New York Academy of Sciences, 2006, 1067, 252-263.	3.8	124
311	Clusterin/Apolipoprotein J up-regulation after zinc exposure, replicative senescence or differentiation of human haematopoietic cells. Biogerontology, 2006, 7, 375-382.	3.9	31
312	The heat shock proteins in cellular aging: is zinc the missing link?. Biogerontology, 2006, 7, 399-408.	3.9	8
313	Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology, 2006, 7, 471-481.	3.9	138
314	Progress in vaccination against cancer 4. Cancer Immunology, Immunotherapy, 2006, 55, 61-62.	4.2	3
315	Immunosenescence, suppression and tumour progression. Cancer Immunology, Immunotherapy, 2006, 55, 981-986.	4.2	53
316	ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank. Cancer Immunology, Immunotherapy, 2006, 55, 623-627.	4.2	42
317	Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands. Cancer Immunology, Immunotherapy, 2006, 56, 101-109.	4.2	36
318	Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunology, Immunotherapy, 2006, 56, 371-379.	4.2	50
319	Immunity and ageing in man. Experimental Gerontology, 2006, 41, 1239-1242.	2.8	123
320	Human cytomegalovirus infection and T cell immunosenescence: A mini review. Mechanisms of Ageing and Development, 2006, 127, 538-543.	4.6	121
321	The immune risk phenotype is associated with IL-6 in the terminal decline stage: Findings from the Swedish NONA immune longitudinal study of very late life functioning. Mechanisms of Ageing and Development, 2006, 127, 695-704.	4.6	239
322	Longitudinal Studies of Clonally Expanded CD8 T Cells Reveal a Repertoire Shrinkage Predicting Mortality and an Increased Number of Dysfunctional Cytomegalovirus-Specific T Cells in the Very Elderly. Journal of Immunology, 2006, 176, 2645-2653.	0.8	447
323	Human T Cell Clones in Long-Term Culture as Models for the Impact of Chronic Antigenic Stress in Aging. , 2006, , 781-792.		6
324	Human immunosenescence: is it infectious?. Immunological Reviews, 2005, 205, 257-268.	6.0	369

#	Article	IF	Citations
325	An investigation of DNA mismatch repair capacity under normal culture conditions and under conditions of supra-physiological challenge in human CD4+T cell clones from donors of different ages. Experimental Gerontology, 2005, 40, 976-981.	2.8	25
326	High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. European Journal of Immunology, 2005, 35, 2876-2885.	2.9	27
327	High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunology, Immunotherapy, 2005, 54, 141-148.	4.2	33
328	Immunosenescence and vaccination. , 2005, 2, 16.		22
329	An Immune Risk Phenotype, Cognitive Impairment, and Survival in Very Late Life: Impact of Allostatic Load in Swedish Octogenarian and Nonagenarian Humans. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 556-565.	3.6	346
330	The Concept of Telomeric Non-Reciprocal Recombination (TENOR) Applied to Human Fibroblasts Grown in Serial Cultures: Concordance with Genealogical Data. Rejuvenation Research, 2005, 8, 154-171.	1.8	3
331	Dysregulation of T-Cell Function in the Elderly. Drugs and Aging, 2005, 22, 589-603.	2.7	111
332	When T Cells Get Old. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe39-pe39.	0.8	3
333	T-CIA: Investigating T Cells in Aging. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe21-pe21.	0.8	1
334	Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 239-51.	2.0	42
335	Immunosenescence. NeuroImmune Biology, 2004, , 9-21.	0.2	0
336	Extrathymic T-cell differentiation in vitro. Nature Reviews Immunology, 2004, 4, 1-2.	22.7	481
337	Activation marker expression and apoptotic susceptibility of T-cell clones derived from CD34+, young and SENIEUR donors. Experimental Gerontology, 2004, 39, 531-538.	2.8	0
338	Dysfunctional CMV-specific CD8+ T cells accumulate in the elderly. Experimental Gerontology, 2004, 39, 607-613.	2.8	166
339	Microsatellite instability in in vitro ageing of T lymphocyte clones. Experimental Gerontology, 2004, 39, 499-505.	2.8	22
340	Effects of a reduced oxygen tension culture system on human T cell clones as a function of in vitro age. Experimental Gerontology, 2004, 39, 525-530.	2.8	14
341	Age related microsatellite instability in T cells from healthy individuals. Experimental Gerontology, 2004, 39, 507-515.	2.8	53
342	Reply to Almanzar's et al. letter to the editor: IFN-gamma production by CMV-specific CD8+ T cells is high in elderly donors. Experimental Gerontology, 2004, 39, 867-868.	2.8	7

#	Article	IF	CITATIONS
343	Nutritional Zinc, Oxidative Stress and Immunosenescence: Biochemical, Genetic, and Lifestyle Implications for Healthy Ageing. Biogerontology, 2004, 5, 271-273.	3.9	19
344	Engineering Anticancer T Cells for Extended Functional Longevity. Annals of the New York Academy of Sciences, 2004, 1019, 178-185.	3.8	11
345	Tumour escape: antitumour effectors too much of a good thing?. Cancer Immunology, Immunotherapy, 2004, 53, 262-274.	4.2	86
346	Tumour escape from the immune response. Cancer Immunology, Immunotherapy, 2004, 53, 843.	4.2	15
347	Immunotherapy and immunoselection - tumour escape as the final hurdle. FEBS Letters, 2004, 567, 63-66.	2.8	28
348	Is immunosenescence infectious?. Trends in Immunology, 2004, 25, 406-410.	6.8	247
349	Immunosenescence and human longevity. Biogerontology, 2003, 4, 167-170.	3.9	15
350	Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. Journal of Clinical Immunology, 2003, 23, 247-257.	3.8	222
351	A lack of telomeric non-reciprocal recombination (TENOR) may account for the premature proliferation blockade of Werner's syndrome fibroblasts. Biogerontology, 2003, 4, 253-273.	3.9	7
352	The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes. Cancer Immunology, Immunotherapy, 2003, 52, 89-96.	4.2	33
353	Editorial statement from Graham Pawelec. Cancer Immunology, Immunotherapy, 2003, 52, 411-412.	4.2	1
354	Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Experimental Gerontology, 2003, 38, 911-920.	2.8	210
355	Development of an MHC-class I peptide selection assay combining nanoparticle technology and matrix-assisted laser desorption/ionisation mass spectrometry. Journal of Immunological Methods, 2003, 283, 205-213.	1.4	8
356	An age-related increase in the number of CD8+ T cells carrying receptors for an immunodominant Epstein–Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mechanisms of Ageing and Development, 2003, 124, 477-485.	4.6	103
357	Immunology and ageing in Europe: ImAginE-ation in the EU. Mechanisms of Ageing and Development, 2003, 124, 357-360.	4.6	2
358	Pathways to a robust immune response in the elderly. Immunology and Allergy Clinics of North America, 2003, 23, 1-13.	1.9	16
359	Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing – a biochemical paradigm for the ageing immune system. Arthritis Research and Therapy, 2003, 5, 290-302.	3.5	74
360	Cytokines and Antitumor Immunity. Technology in Cancer Research and Treatment, 2003, 2, 183-194.	1.9	8

#	Article	IF	Citations
361	Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells. The Hematology Journal, 2003, 4, 57-66.	1.4	21
362	Generation and characterization of human killer cells. Methods in Microbiology, 2002, , 693-706.	0.8	0
363	Alterations in signal transduction in Ilymphocytes and neutrophils with ageing. Advances in Cell Aging and Gerontology, 2002, 13, 93-121.	0.1	1
364	Cultured T cell clones as models for immunosenescence. Advances in Cell Aging and Gerontology, 2002, , 295-307.	0.1	1
365	Chronic Phase CML Patients Possess T Cells Capable of Recognising Autologous Tumour Cells. Leukemia and Lymphoma, 2002, 43, 943-951.	1.3	6
366	T cells and aging january 2002 update. Frontiers in Bioscience - Landmark, 2002, 7, d1056-1183.	3.0	347
367	Basic biology and clinical impact of immunosenescence. Experimental Gerontology, 2002, 37, 183-189.	2.8	53
368	Human CD4+ T cell clone longevity in tissue culture: lack of influence of donor age or cell origin. Experimental Gerontology, 2002, 37, 265-269.	2.8	37
369	Mitochondrial DNA damage in lymphocytes: a role in immunosenescence?. Experimental Gerontology, 2002, 37, 329-340.	2.8	32
370	Is human aging still mysterious enough to be left only to scientists?. BioEssays, 2002, 24, 667-676.	2.5	52
371	Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124–138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunology, Immunotherapy, 2002, 51, 271-281.	4.2	37
372	Immunogenicity of WT-1 peptides. Cancer Immunology, Immunotherapy, 2002, 51, 349-349.	4.2	2
373	HER-2/neu-derived peptide 884–899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones. Cancer Immunology, Immunotherapy, 2002, 50, 615-624.	4.2	45
374	Escape Mechanisms in Tumor Immunity: An Update. Journal of Environmental Pathology, Toxicology and Oncology, 2002, 21, 54.	1.2	13
375	Escape mechanisms in tumor immunity: an update. Journal of Environmental Pathology, Toxicology and Oncology, 2002, 21, 277-330.	1.2	6
376	Compromised interferon gamma (IFN-gamma) production in the elderly to both acute and latent viral antigen stimulation: contribution to the immune risk phenotype?. European Cytokine Network, 2002, 13, 392-4.	2.0	25
377	MHC class II-restricted tumor antigens and CD4+ T cells play a role in hematological malignancies as well as solid tumors. Trends in Immunology, 2001, 22, 422-423.	6.8	6
378	Generation of Chronic Myelogenous Leukemia-Specific T Cells in Cytokine-Modified Autologous Mixed Lymphocyte/Tumor Cell Cultures. Journal of Immunotherapy, 2001, 24, 482-492.	2.4	6

#	Article	IF	Citations
379	The self peptide annexin II (208–223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells. Cancer Immunology, Immunotherapy, 2001, 49, 671-678.	4.2	11
380	Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells. British Journal of Haematology, 2001, 112, 740-748.	2.5	18
381	A multidisciplinary approach to immunity and ageing: ImAginEering. Mechanisms of Ageing and Development, 2001, 121, 1-4.	4.6	4
382	Hypothesis: loss of telomerase inducibility and subsequent replicative senescence in cultured human T cells is a result of altered costimulation. Mechanisms of Ageing and Development, 2001, 121, 181-185.	4.6	17
383	The SENIEUR protocol after 16 years. Mechanisms of Ageing and Development, 2001, 122, 132-134.	4.6	81
384	Age-related accumulation of oxidative DNA damage and alterations in levels of p16INK4a/CDKN2a, p21WAF1/CIP1/SDI1 and p27KIP1 in human CD4+ T cell clones in vitro. Mechanisms of Ageing and Development, 2001, 122, 1151-1167.	4.6	44
385	Altered T cell signalling in ageing. Mechanisms of Ageing and Development, 2001, 122, 1613-1637.	4.6	123
386	Escape Mechanisms in Tumour Immunity. , 2001, , 219-247.		1
387	Longevity in vitro of human CD4+ T helper cell clones derived from young donors and elderly donors, or from progenitor cells: age-associated differences in cell surface molecule expression and cytokine secretion. Biogerontology, 2000, 1, 247-254.	3.9	24
388	Defensins are dominant HLA-DR-associated self-peptides from CD34â^ peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia). Blood, 2000, 95, 2890-2896.	1.4	22
389	Human T-Cell Clones. , 2000, 38, 53-61.		0
390	Telomeres and Telomerase. Rejuvenation Research, 2000, 3, 361-363.	0.2	0
391	Anti-Aging Medicine LiteratureWatch. Rejuvenation Research, 2000, 3, 207-221.	0.2	0
392	In vitro senescence models for human T lymphocytes. Vaccine, 2000, 18, 1666-1674.	3.8	40
393	Anti-Aging Medicine LiteratureWatch. Rejuvenation Research, 2000, 3, 113-126.	0.2	0
394	T cells and aging (update February 1999). Frontiers in Bioscience - Landmark, 1999, 4, d216.	3.0	109
395	Telomere-dependent senescence. Nature Biotechnology, 1999, 17, 313-313.	17.5	37
396	Anti-Aging Medicine LiteratureWatch. Rejuvenation Research, 1999, 2, 165-182.	0.2	0

#	Article	IF	CITATIONS
397	Importance of T-Cell Replicative Senescence for the Adoptive Immunotherapy of Cancer in Humans?. Rejuvenation Research, 1999, 2, 115-120.	0.2	1
398	Anti-Aging Medicine LiteratureWatch. Rejuvenation Research, 1999, 2, 85-101.	0.2	1
399	Anti-Aging Medicine LiteratureWatch. Rejuvenation Research, 1999, 2, 295-309.	0.2	0
400	Prerequisites for the Immunotherapy of Cancer. Cancer Immunology, Immunotherapy, 1999, 48, 214-217.	4.2	5
401	Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?. Cancer Immunology, Immunotherapy, 1999, 48, 343-345.	4.2	36
402	IFN-α regulates IL 10 production by CML cells in vitro. Cancer Immunology, Immunotherapy, 1999, 48, 430-434.	4.2	11
403	Finite lifespans of t cell clones derived from CD34+ human haematopoietic stem cells in vitro. Experimental Gerontology, 1999, 34, 69-77.	2.8	16
404	T cell immunosenescence in vitro and in vivo. Experimental Gerontology, 1999, 34, 419-429.	2.8	74
405	Age-related changes in the expression of CD95 (APO1/FAS) on blood lymphocytesâ ⁺ . Experimental Gerontology, 1999, 34, 659-673.	2.8	73
406	Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunology, Immunotherapy, 1998, 47, 32-38.	4.2	78
407	Anti-Aging Medicine LiteratureWatch. Rejuvenation Research, 1998, 1, 275-284.	0.2	0
408	Impact of aging on innate immunity. Journal of Leukocyte Biology, 1998, 64, 703-712.	3.3	138
409	Extrathymic T cell differentiation <i>in vitro</i> from human CD34+ stem cells. Journal of Leukocyte Biology, 1998, 64, 733-739.	3.3	27
410	T-cell immunosenescence and its clinical relevance in man. Reviews in Clinical Gerontology, 1998, 8, 5-14.	0.5	47
411	T cells and aging. Frontiers in Bioscience - Landmark, 1998, 3, d59-99.	3.0	96
412	The T cell in the ageing individual 1 This article is based on a presentation to the First International Conference on Aging and Immunology, Bethesda, MD, 16–19 June, 1996.1. Mechanisms of Ageing and Development, 1997, 93, 35-45.	4.6	104
413	Human T-cell clones in long-term culture as a model of immunosenescence. Immunological Reviews, 1997, 160, 31-42.	6.0	101
414	Interleukin-13 secretion by normal and posttransplant T lymphocytes; in vitro studies of cellular immune responses in the presence of acute leukaemia blast cells. Cancer Immunology, Immunotherapy, 1997, 45, 45-52.	4.2	5

#	Article	IF	CITATIONS
415	Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion?. Trends in Immunology, 1997, 18, 450-454.	7. 5	336
416	Escape from Host-Antitumor Immunity. Critical Reviews in Oncogenesis, 1997, 8, 111-142.	0.4	72
417	A peptide from the known HLA class I restricted melanoma-specific tumor antigen GP100 is presented by HLA-DR in the melanoma cell line FM3. Human Immunology, 1996, 47, 22.	2.4	O
418	INTERLEUKIN 10 PROTECTS ACTIVATED HUMAN T LYMPHOCYTES AGAINST GROWTH FACTOR WITHDRAWAL-INDUCED CELL DEATH BUT ONLY ANTI-FAS ANTIBODY CAN PREVENT ACTIVATION-INDUCED CELL DEATH. Cytokine, 1996, 8, 877-881.	3.2	15
419	Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; studies of normal polyclonal T cells and T lymphocyte clones derived early after allogeneic bone marrow transplantation. Cancer Immunology, Immunotherapy, 1996, 42, 133-140.	4.2	4
420	Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunology, Immunotherapy, 1996, 42, 193-199.	4.2	27
421	Decreased proliferative capacity and increased susceptibility to activation-induced cell death in late-passage human cd4+ tcr2+ cultured T cell clones. Experimental Gerontology, 1996, 31, 655-668.	2.8	62
422	The Role of Endogenous Peptides in the Direct Pathway of Alloreactivity to Human MHC Class II Molecules Expressed on CHO Cells. Immunological Reviews, 1996, 154, 155-173.	6.0	7
423	CYTOKINE MODULATION OF TH1/TH2 PHENOTYPE DIFFERENTIATION IN DIRECTLY ALLORESPONSIVE CD4+ HUMAN T CELLS1. Transplantation, 1996, 62, 1095-1101.	1.0	23
424	In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation. Cancer Chemotherapy and Pharmacology, 1995, 37, 70-78.	2.3	7
425	Cytokine modulation of interleukin 1 and tumour necrosis factor- $\hat{l}\pm$ secretion from acute myelogenous leukaemia blast cells in vitro. Leukemia Research, 1995, 19, 15-22.	0.8	20
426	Human $\hat{I}^3\hat{I}'$ Cells Are Resistant to Induction of Anergy but Not to Induction of Cell Death in Vitro. Cellular Immunology, 1995, 162, 8-15.	3.0	4
427	Relative Roles of Natural Killer- and T Cell-Mediated Anti-Leukemia Effects in Chronic Myelogenous Leukemia Patients Treated with Interferon-α. Leukemia and Lymphoma, 1995, 18, 471-478.	1.3	36
428	Molecular and cell biological studies of ageing and their application to considerations of T lymphocyte immunosenescence. Mechanisms of Ageing and Development, 1995, 79, 1-32.	4.6	63
429	Long-term culture of monoclonal human T lymphocytes: models for immunosenescence?. Mechanisms of Ageing and Development, 1995, 83, 171-183.	4.6	72
430	Interleukin 10 is a human T cell growth factor in vitro. Cytokine, 1995, 7, 355-363.	3.2	15
431	MHC-Unrestricted Immune Surveillance of Leukemia1. Cancer Biotherapy, 1994, 9, 265-288.	0.5	5
432	Requirements for Stimulation or Anergy Induction in Alloreactive Human T Cell Clones. Cellular Immunology, 1994, 158, 241-252.	3.0	6

#	Article	IF	CITATIONS
433	Human T-cell receptor TCRAV, TCRBV, and TCRAJ sequences newly found in T-cell clones reactive with allogeneic HLA class II antigens. Immunogenetics, 1993, 38, 67-70.	2.4	10
434	Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. British Journal of Haematology, 1993, 84, 356-358.	2.5	147
435	Effects of dipyridamole and R-verapamil on in vitro proliferation of blast cells from patients with acute myelogenous leukaemia. Leukemia Research, 1993, 17, 507-513.	0.8	10
436	Induction of Hyporesponsiveness in Human Lymphocytes-T Despite Their Expression of both the Co-receptor CD28 and Its Ligand B7. Cellular Immunology, 1993, 151, 283-290.	3.0	5
437	Suppressor cells in transplantation immunology: do recent advances in T cell immunobiology and cytokine networking contribute to the solution of an old conundrum?. Transplant Immunology, 1993, 1, 172-181.	1.2	8
438	A single universal primer for the T-Cell receptor (TCR) variable genes enables enzymatic amplification and direct sequencing of $TCR\hat{1}^2$ cDNA of various T-cell clones. Human Immunology, 1993, 36, 163-167.	2.4	12
439	Evolution of a CD3+/CD+ \hat{I} ±/ \hat{I} ² T-Cell Receptor+Mature T-Cell Clone from CD3-CD7+Sorted Human Bone Marrow Cells. Autoimmunity, 1993, 3, 197-210.	0.6	10
440	IFNâ€Î³ and TNFâ€Î± secretion by CD4 ⁺ and CD8 ⁺ TCRαβ ⁺ Tâ€cell clones early after allogeneic bone marrow transplantation. European Journal of Haematology, 1993, 51, 73-79.	derived	13
441	Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue Annals of the Rheumatic Diseases, 1992, 51, 731-734.	0.9	166
442	CD4+ TCRαβ+ T-cell clones derived shortly after allogeneic bone marrow transplantation: Theophyllamine and verapamil inhibit proliferation of functionally heterogeneous T-cells. International Journal of Immunopharmacology, 1992, 14, 783-789.	1,1	5
443	LACK OF ASSOCIATION BETWEEN THE FREQUENCIES OF HLA-DR OR HLA-DP ALLELES AND THE OCCURRENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE. Transplantation, 1991, 51, 917.	1.0	0
444	CD4+TCRαβ+ T-cells developing after allogeneic bone marrow transplantation in patients with chronic myelogenous leukaemia. Dipyridamole inhibits functionally heterogeneous T-cell clones. International Journal of Immunopharmacology, 1991, 13, 1127-1135.	1.1	4
445	Conditions for the generation of autoreactive human T cell clones: Requirement for lymphokines other than interleukin 2 alone. Cellular Immunology, 1991, 134, 265-275.	3.0	1
446	Cytotoxic and noncytotoxic mechanisms involved in the in vitro anti-leukaemia effects of T cell clones established from a chronic myelogenous leukaemia patient during treatment in vivo with interferon \hat{l}_{\pm} . Cancer Immunology, Immunotherapy, 1991, 33, 54-60.	4.2	6
447	Clinical trial of natural human lymphocyte-derived interleukin 2 in cancer patients: Effects on cytokine production and suppressor cell status. Biotherapy (Dordrecht, Netherlands), 1991, 3, 309-318.	0.7	3
448	Phenotypic and Functional Characterization of Tumor Infiltrating Lymphocytes in Mycosis Fungoides: Continuous Growth of CD4+ CD45R+ T-Cell Clones with Suppressor-Inducer Activity. Journal of Investigative Dermatology, 1990, 94, 304-309.	0.7	20
449	Involvement of CD45 in MHC Class II-allospecific cytotoxicity. Cellular Immunology, 1990, 127, 514-519.	3.0	2
450	Human T cell clones with $\hat{l}^3\hat{l}$ and $\hat{l}^2\hat{l}^2$ receptors are differently stimulated by monoclonal antibodies to CD2. Cellular Immunology, 1990, 129, 385-393.	3.0	13

#	Article	IF	Citations
451	Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-î±-treated chronic myelogenous leukaemia patients. Cancer Immunology, Immunotherapy, 1990, 32, 167-172.	4.2	10
452	Differential secretion of tumor necrosis factor- \hat{l} ± and granulocyte/macrophage colony-stimulating factors but not interferon- \hat{l} 3 from CD4 compared to CD8 human T cell clones. European Journal of Immunology, 1989, 19, 197-200.	2.9	36
453	Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside. Cancer Immunology, Immunotherapy, 1989, 29, 242-6.	4.2	8
454	Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-? (wellferon). Cancer Immunology, Immunotherapy, 1989, 29, 63-6.	4.2	19
455	Involvement of "accessory―and antigen receptor molecules in human helper T cell clone activation studied by monoclonal antibody inhibition. Human Immunology, 1989, 24, 41-50.	2.4	3
456	PREDICTIVE STRENGTH OF MIXED LYMPHOCYTE CULTURES FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS TRANSPLANTED WITH HLA-IDENTICAL SIBLING BONE MARROW. Transplantation, 1989, 48, 890.	1.0	8
457	Human leukocyte antigen-DP in leukemia. Cancer, 1988, 61, 475-477.	4.1	14
458	Division of human helper T cells into two sets on the basis of the induction of anti-tumor cytotoxicity by phorbol ester and calcium ionophore. European Journal of Immunology, 1988, 18, 1147-1150.	2.9	8
459	Lymphoma-specific T- and B-cell responses suggest the involvement of HTLV-I in virus-non-productive lymphomas of a married couple. International Journal of Cancer, 1988, 41, 548-556.	5.1	0
460	Cyclosporin A blocks the generation of alloindifferent but not of allospecific suppressive cells. Immunology Letters, 1988, 18, 293-296.	2.5	2
461	Cellular immunological defects of chronic myelogenous leukaemics: partial dependence on busulphan therapy. Cancer Immunology, Immunotherapy, 1988, 27, 89-94.	4.2	13
462	Regulation of allospecific suppressive cell generation in vitro. Immunology Letters, 1988, 19, 121-126.	2.5	4
463	Different signals for stimulation of proliferation and lymphokine secretion by a CD3+ WT31â^ cloned cytotoxic lymphocyte. Cellular Immunology, 1988, 113, 329-340.	3.0	10
464	PRETREATMENT OF CHRONIC MYELOGENOUS LEUKEMIC BLOOD SAMPLES WITH CYTOSINE ARABINOSIDE PRIOR TO MIXED LYMPHOCYTE CULTURE TYPING. Transplantation, 1988, 46, 607.	1.0	3
465	GENERATION OF CD4-POSITIVE SUPPRESSOR T CELLS FROM MIXED LYMPHOCYTE CULTURES IN THE PRESENCE OF INTERLEUKIN 2 RECEPTOR ANTIBODY TÜ69. Transplantation, 1987, 44, 295-302.	1.0	12
466	Alloreactive T-lymphocyte clones detecting epitodes uniquely expressed on HLA-D homozygous cells. Human Immunology, 1987, 19, 279-286.	2.4	2
467	HLA-DQw3 dissected by cloned alloreactive T cells. Immunogenetics, 1987, 25, 356-358.	2.4	6
468	Constitutive Functional Heterogeneity without Detectable Somatic Mutation of Antigen Receptor Genes in Helper T Cell Clones: Possible Regulation by Novel HLA Class II "DY" Determinants*. Immunological Reviews, 1987, 96, 109-140.	6.0	6

#	Article	IF	CITATIONS
469	Dissection of suppressor cell generation in vitro. Human Immunology, 1986, 17, 343-354.	2.4	11
470	Heterogeneity of human natural killer recognition demonstrated by cloned effector cells and differential blocking of cytotoxicity with monoclonal antibodies. Cellular Immunology, 1985, 92, 31-40.	3.0	9
471	HLA-DR-, MB- and novel DC-related determinants restrict purified protein derivative of tuberculin (PPD)- stimulated human T cell proliferation. European Journal of Immunology, 1985, 15, 12-17.	2.9	22
472	Function of alloproliferative T lymphocyte clones correlates better with their class II recognitive specificity than with their cell surface phenotype. European Journal of Immunology, 1985, 15, 163-167.	2.9	6
473	Homozygous typing cell-defined HLA-Dw specificities correlate better than serologically defined HLA-DR specificities with restriction elements for influenza virus-specific proliferative human T lymphocyte clones. Human Immunology, 1985, 14, 37-47.	2.4	9
474	Cloned human T lymphocytes with lymphostimulatory capacity preferentially activate suppressor cells. European Journal of Immunology, 1984, 14, 335-340.	2.9	20
475	Human T-cell clones with multiple and changing functions: indications of unexpected flexibility in immune response networks?. Trends in Immunology, 1983, 4, 275-278.	7.5	38
476	Allogeneically primed T lymphocyte clones in the analysis of lymphocyte stimulatory determinants. Human Immunology, 1983, 8, 239-247.	2.4	32
477	Constitutive interleukin 2 production by the JURKAT human leukemic T cell line. European Journal of Immunology, 1982, 12, 387-392.	2.9	37
478	surface markers of mono-and multi-functional mixed leukocyte culture-derived T cell clones in man. European Journal of Immunology, 1982, 12, 607-615.	2.9	40
479	Alloactivated long-term cultured human T lymphocytes express both HLA-DR and SB antigens but lack lymphocyte stimulation capacity. European Journal of Immunology, 1982, 12, 967-972.	2.9	26
480	Immunohistology of graft-versus-host disease mediated skin lesions and its correlation to a large granular lymphocyte surface phenotype and function. Blut, 1982, 44, 89-94.	1.2	17
481	CYCLOSPORIN A. Transplantation, 1979, 27, 55-58.	1.0	126
482	Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. Frontiers in Immunology, 0, 13, .	4.8	2